Welcome To Achilles Therapeutics
Achilles Therapeutics is a biopharmaceutical company developing personalised T cell therapies targeting neoantigens: protein markers unique to each individual that are present on the surface of a cancer cell and can be detected by the immune system. Our approach is based on the science of tumour evolution which allows us to identify neoantigens that arise early in the cancer’s development and are retained as each tumour grows. These ‘clonal’ neoantigens are present on all the cancer cells and are completely absent from a patient’s healthy tissue. By directing T cells therapies to clonal neoantigens we can for the first time target every cancer cell without attacking healthy tissue.
The Science
Achilles was founded by world-leading experts in cancer evolution, bioinformatics and the development of cell-based immunotherapies. The company brings together these disciplines to develop next-generation, patient-specific cell therapies that harness the immune system to destroy cancer cells.
PROFESSOR CHARLIE SWANTON
Co-founder Charlie Swanton speaks about his career, the advent of immunotherapy and what the Achilles team are looking to achieve.
THE ACHILLES FOUNDERS
Iraj Ali, Charlie Swanton and Karl Peggs discuss the dosing of the first melanoma patient with a cell therapy to specifically target all cancer cells. This marks a significant milestone for Achilles, delivering the first precision TIL therapy.